Dr. Trapnell received his medical degree from the University of Maryland in 1985 and medical residency training at The Ohio State University Hospitals. He completed a fellowship in pulmonary medicine and then served as attending physician and senior attending physician at the Clinical Center of the National Institutes of Health. Subsequently, he served as vice president and director of the Division of Pulmonary and Virology Studies at Genetic Therapy, Incorporated, a subsidiary of Novartis.
In 1997, Dr. Trapnell joined Cincinnati Children’s Hospital Medical Center and is now a professor of Medicine and Pediatrics at the UC College of Medicine. At Cincinnati Children's, he directed Cincinnati’s Cystic Fibrosis Therapeutics Development Network Center for more than a decade and participated in numerous clinical trials as principal investigator including studies leading to FDA-approval of Creon® and Pancreaze®. He established and directs the Rare Lung Diseases Clinical Research Consortium (RLDC) in which a study led by Frank McCormack resulted in FDA approval of Sirolimus® as therapy of Lymphangioleiomyomatosis.
Dr. Trapnell’s research group established that GM-CSF autoantibodies caused the rare lung disease autoimmune pulmonary alveolar proteinosis and established clinical laboratory tests for its diagnosis and identified hereditary pulmonary alveolar proteinosis as a new genetic disease caused by mutations in CSF2RA and CSF2RB. His research group developed a novel type of cell transplantation, pulmonary macrophage transplantation, and is currently translating it for testing as therapy in patients with the disease. The group also contributed to the identification, characterization, and methods for diagnosis of indium-related lung disease.
An ardent patient advocate, Dr. Trapnell has worked with patient foundations for cystic fibrosis (CF), alpha-1-antitrypsin deficiency, pulmonary alveolar proteinosis, lymphangioleiomyomatosis, and childhood interstitial lung diseases. He has served as past scientific director for the Alpha-1 Foundation and as co-founder and current scientific director of the Pulmonary Alveolar Proteinosis Foundation. Since coming to Cincinnati, he has provided training in basic, clinical, and translational research at pre- and post-doctoral levels.
BS: Biochemistry, University of Maryland, College Park, MD, 1978.
MS: Genetics, The George Washington University, Washington, DC, 1981.
MD: University of Maryland School of Medicine, Baltimore, MD, 1984.
Residency: Internal Medicine, The Ohio State University Hospitals, Columbus, OH, 1987.
Fellowship: Pulmonary Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, 1989.
Certification: Diplomat in Internal Medicine, American Board of Internal Medicine, 1987; Diplomat, National Board of Medical Examiners, 1987; Diplomat in Pulmonary Medicine, American Board of Internal Medicine, 2000.
Research on rare lung diseases including pulmonary alveolar proteinosis; cystic fibrosis; alpha-1 antitrypsin deficiency; lymphangioleiomyomatosis
Pulmonary Medicine, Cystic Fibrosis Center
Alveolar macrophage function; molecular techniques using gene knockout, transgenic and conditional gene expression mouse models and non-human primates, in vitro and in vivo viral gene transfer, and bone marrow transplantation
An exploratory study investigating biomarkers associated with autoimmune pulmonary alveolar proteinosis (aPAP). Scientific Reports. 2022; 12.
Two-year follow-up of exposure, engineering controls, respiratory protection and respiratory health among workers at an indium-tin oxide (ITO) production and reclamation facility. Occupational and Environmental Medicine. 2022; 79:550-556.
Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis. Arthritis and Rheumatology. 2022; 74:1271-1283.
Signal Transducer and Activator of Transcription 5B Deficiency-associated Lung Disease. American Journal of Respiratory and Critical Care Medicine. 2022; 205:1245-1250.
Autoimmune Pulmonary Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine. 2022; 205:1016-1035.
Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases. 2022; 81:653-661.
A murine model of hereditary pulmonary alveolar proteinosis caused by homozygous Csf2ra gene disruption. American Journal of Physiology - Lung Cellular and Molecular Physiology. 2022; 322:L438-L448.
Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. Rheumatology. 2021; 3:e410-e418.
Whole-Lung Lavage. Diagnostic and Interventional Bronchoscopy in Children. 2021.
Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis. New England Journal of Medicine. 2020; 383:1635-1644.
Bruce C. Trapnell, MS, MD9/7/2020
Bruce C. Trapnell, MS, MD7/1/2019
Bruce C. Trapnell, MS, MD6/28/2019
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey